At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 42 enrolled
Drug / intervention
Cholestyramine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-Blind, Single Research Site, Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale in Generally Healthy Subjects
Louisville Metabolic and Atherosclerosis Research Center·interventional·Posted May 13, 2010·Updated Oct 7, 2010
In Brief
A Phase 4 clinical trial evaluating Cholestyramine and Colesevelam HCl for Healthy. Completed, enrolled 42 participants across 1 site.
Detailed Summary
The objective of this study is to compare the acceptability of Colesevelam HCl powder for oral suspension versus generic cholestyramine via the BASA scale, based upon an anticipated equivalent cholesterol lowering doses of each comparator drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsProvident Clinical Research, Daiichi Sankyo
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionJun 2010
TodayJul 2026
First PostedMay 13, 2010
Enrollment StartApr 1, 2010
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.1 years ago
Interventions
Cholestyraminedrug
Cholestyramine 12 grams, one time dose
Colesevelam HCldrug
Colesevelam HCl, 4 grams, one time dose